Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Kyntra Bio (Nasdaq: KYNB) will present at the 25th Annual Needham Virtual Healthcare Conference April 13-16, 2026. CEO Thane Wettig will deliver the company presentation on April 13, 2026 at 1:30 PM EDT. A live webcast and a 90-day replay will be available on the company website.
Management will be available for one-on-one meetings via Needham representative requests.
Positive
- None.
Negative
- None.
News Market Reaction – KYNB
In the Apr 9 session, KYNB declined 1.51%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 16 | Earnings and update | Positive | +5.3% | Q4/FY2025 financials plus clinical and cash runway updates. |
| Mar 09 | Earnings date set | Neutral | +7.3% | Announcement of timing for Q4/FY2025 results and conference call. |
| Feb 23 | Clinical data update | Positive | -9.6% | Positive Phase 1b/2 data for FG-3246 combo in mCRPC. |
| Feb 17 | Investor conferences | Neutral | +6.3% | Planned participation in Oppenheimer and Leerink healthcare conferences. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
KYNB has seen positive reactions to earnings and conference participation, but a notable divergence where positive clinical data coincided with a sharp decline.
Over recent months, Kyntra Bio reported Q4/FY2025 results and clinical updates on Mar 16, 2026, with shares gaining after the announcement. The earnings-date notice on Mar 9, 2026 also saw a positive move. Earlier, positive Phase 1b/2 data for FG-3246 on Feb 23, 2026 was followed by a marked selloff, contrasting with gains around investor conference participation disclosed on Feb 17, 2026. Today’s Needham conference appearance fits this pattern of ongoing investor outreach.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, April 08, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the Company will present at the 25th Annual Needham Virtual Healthcare Conference being held April 13-16, 2026.
Thane Wettig, Chief Executive Officer of Kyntra Bio, will deliver a company presentation on Monday, April 13, 2026, at 1:30 PM EDT. A live webcast of the presentation will be available here.
Kyntra Bio’s management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at Needham. A replay of the presentation will be posted, when available, to the Kyntra Bio website on the Events & Presentations page of the Investors and Media section for 90 days.
About Kyntra Bio
Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in Europe, Japan, China, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.kyntrabio.com.
For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
ir@kyntrabio.com
